Oregon 2023 Regular Session

Oregon House Bill HB3299

Introduced
2/21/23  
Refer
2/23/23  

Caption

Relating to opioid reversal medications.

Impact

The introduction of HB 3299 is expected to significantly impact public health policy in Oregon. By establishing the Opioid Reversal Medication Bulk Purchasing Fund, the bill provides a structured financial framework to facilitate the procurement of these lifesaving drugs. Funding for the program will come from opioid litigation settlements, grants, and other donations, ensuring that financial resources are dedicated to minimizing the public health crisis caused by opioid overdoses. This proactive approach highlights the state’s commitment to reducing overdose deaths and supporting individuals who are vulnerable to substance abuse issues.

Summary

House Bill 3299 is a legislative measure aimed at tackling the opioid overdose crisis in Oregon. It mandates the administrator of the Oregon Prescription Drug Program to undertake bulk purchases of opioid reversal medications, thereby expanding the availability of such medications to various entities that serve vulnerable populations, including hospitals, first responders, law enforcement, courts, and organizations providing services to the homeless. This initiative is designed to ensure that essential reversal medications, which can save lives during opioid overdoses, are widely accessible across the state.

Sentiment

Overall, the sentiment surrounding HB 3299 has been positive, with widespread support for its intentions to combat the serious public health challenge posed by opioid overdoses. Legislators, health officials, and community organizations largely view the bill as a necessary step toward improving access to critical health resources. However, there may be concerns about the implementation process and ensuring that the medications reach the intended beneficiaries effectively, which could spur discussions on logistics and operational transparency.

Contention

While HB 3299 has garnered support, some points of contention might arise regarding the distribution mechanisms for the opioid reversal medications. There could be debates about which entities should be prioritized for receiving these medications and the most efficient ways to ensure they are used effectively in overdose situations. Additionally, ongoing discussions about funding levels and the sustainability of the proposed Bulk Purchasing Fund may influence the bill's overall effectiveness and public acceptance.

Companion Bills

No companion bills found.

Previously Filed As

OR HB2397

Relating to opioid overdose prevention.

OR SB1043

Relating to opioid overdose reversal medication.

OR SB472

Pupil health: opioid overdose reversal medication.

OR HB358

AN ACT relating to opioid overdose reversal agents.

OR HB3613

Relating to pharmaceutical purchasing; prescribing an effective date.

OR AB2998

Opioid overdose reversal medications: pupil administration.

OR LD1728

An Act to Ensure Access to Federally Approved Opioid Overdose-reversing Medication

OR HB1227

Opioid overdose reversal medication in schools.

OR HB2395

Relating to substance use; and declaring an emergency.

OR H2217

Relative to opioid reversal drugs

Similar Bills

No similar bills found.